文献速递消化系统肿瘤骨软组织肉瘤与黑色素瘤

利用RAF与MEK抑制剂的变构特性靶向BRAF信号驱动的耐药肿瘤

Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.
PubMed 文献 · Cancer Discov · 2021-02-10

该研究识别了一类选择性抑制二聚体BRAF(dBRAF)而非单体BRAF(mBRAF)的RAF抑制剂,分子动力学模拟揭示其选择性源于限制BRAF αC-螺旋运动。基于构象选择性联合mBRAF选择性抑制剂、dBRAF选择性抑制剂及最强BRAF-MEK破坏性MEK抑制剂的三联方案,在BRAFV600E治疗耐药模型中抑制肿瘤生长且无毒性,并在一位IV期结直肠癌患者中实现持久缓解和临床状况改善。

要点

  • 识别出选择性抑制dBRAF而非mBRAF的第三类RAF抑制剂。
  • 基于构象选择性的三联方案在耐药模型中有效且无毒性。
  • 三联方案在IV期结直肠癌患者中实现持久缓解。

核心结论

  • 利用RAF和MEK抑制剂的变构特性可设计对BRAFV600E肿瘤有效且耐受性好的疗法。

研究设计与样本

  • 研究包括分子动力学模拟、BRAFV600E治疗耐药模型的临床前实验及一例IV期结直肠癌患者的临床观察。

主要发现

  • 分子动力学模拟显示限制BRAF αC-螺旋运动是抑制剂选择性的基础。
  • 基于构象选择性的三联方案在BRAFV600E治疗耐药模型中促进肿瘤生长抑制。
  • 三联方案未显示毒性,而dBRAF选择性抑制剂联合MEK抑制剂导致小鼠体重下降。
  • 三联方案在一位IV期结直肠癌患者中实现持久缓解并改善临床状况。

临床怎么用

  • 基于RAF和MEK抑制剂的构象选择性进行合理联合,可能为BRAFV600E肿瘤提供有效且耐受性好的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current clinical RAF inhibitors (RAFi) inhibit monomeric BRAF (mBRAF) but are less potent against dimeric BRAF (dBRAF). RAFi equipotent for mBRAF and dBRAF have been developed but are predicted to have lower therapeutic index. Here we identify a third class of RAFi that selectively inhibits dBRAF over mBRAF. Molecular dynamic simulations reveal restriction of the movement of the BRAF αC-helix as the basis of inhibitor selectivity. Combination of inhibitors based on their conformation selectivity (mBRAF- plus dBRAF-selective plus the most potent BRAF-MEK disruptor MEK inhibitor) promoted suppression of tumor growth in BRAFV600E therapy-resistant models. Strikingly, the triple combination showed no toxicities, whereas dBRAF-selective plus MEK inhibitor treatment caused weight loss in mice. Finally, the triple combination achieved durable response and improved clinical well-being in a patient with stage IV colorectal cancer. Thus, exploiting allosteric properties of RAF and MEK inhibitors enables the design of effective and well-tolerated therapies for BRAFV600E tumors. SIGNIFICANCE: This work identifies a new class of RAFi that are selective for dBRAF over mBRAF and determines the basis of their selectivity. A rationally designed combination of RAF and MEK inhibitors based on their conformation selectivity achieved increased efficacy and a high therapeutic index when used to target BRAFV600E tumors.See related commentary by Zhang and Bollag, p. 1620.This article is highlighted in the In This Issue feature, p. 1601.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Adamopoulos C, Ahmed TA, Tucker MR, et al. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discov. 2021. PMID: 33568355. doi:10.1158/2159-8290.CD-20-1351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。